Glenmede Trust Co. NA Invests $575,000 in Savara Inc. $SVRA

Glenmede Trust Co. NA purchased a new stake in shares of Savara Inc. (NASDAQ:SVRA) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 105,273 shares of the company’s stock, valued at approximately $575,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bank of America Corp DE raised its position in Savara by 38.9% in the 1st quarter. Bank of America Corp DE now owns 588,199 shares of the company’s stock worth $3,212,000 after purchasing an additional 164,603 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Savara in the 1st quarter valued at $247,000. ADAR1 Capital Management LLC raised its position in shares of Savara by 4.2% during the first quarter. ADAR1 Capital Management LLC now owns 1,464,535 shares of the company’s stock worth $7,996,000 after acquiring an additional 59,083 shares during the last quarter. Eversept Partners LP raised its position in shares of Savara by 125.8% during the first quarter. Eversept Partners LP now owns 384,264 shares of the company’s stock worth $2,098,000 after acquiring an additional 214,069 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Savara by 56.6% during the first quarter. The Manufacturers Life Insurance Company now owns 68,175 shares of the company’s stock valued at $372,000 after acquiring an additional 24,628 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. Finally, Oppenheimer began coverage on shares of Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.14.

Savara Trading Up 0.7%

NASDAQ SVRA opened at $5.83 on Friday. The stock has a 50-day simple moving average of $5.62 and a 200 day simple moving average of $5.50. The company has a market capitalization of $1.19 billion, a PE ratio of -10.41 and a beta of 0.29. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. Savara Inc. has a 12 month low of $2.43 and a 12 month high of $7.01.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Research analysts forecast that Savara Inc. will post -0.57 EPS for the current year.

Savara Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.